Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Receivables (2016 - 2021)

Viridian Therapeutics, Inc.\DE has reported Receivables over the past 8 years, most recently at $1.5 million for Q3 2021.

  • Quarterly results put Receivables at $1.5 million for Q3 2021, up 2494.74% from a year ago — trailing twelve months through Sep 2021 was $1.5 million (up 2494.74% YoY), and the annual figure for FY2019 was $6000.0, changed.
  • Receivables for Q3 2021 was $1.5 million at Viridian Therapeutics, Inc.\DE, up from $57000.0 in the prior quarter.
  • Over the last five years, Receivables for VRDN hit a ceiling of $5.8 million in Q1 2018 and a floor of $4000.0 in Q1 2020.
  • Median Receivables over the past 5 years was $979000.0 (2019), compared with a mean of $1.1 million.
  • Biggest five-year swings in Receivables: plummeted 99.9% in 2019 and later skyrocketed 2494.74% in 2021.
  • Viridian Therapeutics, Inc.\DE's Receivables stood at $2.6 million in 2017, then plummeted by 99.06% to $24000.0 in 2018, then soared by 3979.17% to $979000.0 in 2019, then crashed by 94.18% to $57000.0 in 2020, then skyrocketed by 2494.74% to $1.5 million in 2021.
  • The last three reported values for Receivables were $1.5 million (Q3 2021), $57000.0 (Q3 2020), and $248000.0 (Q2 2020) per Business Quant data.